Enzrid-DS Tablet is a pharmaceutical formulation combining Bromelain (180 mg), Trypsin (96 mg), and Rutoside (200 mg), designed to provide potent anti-inflammatory, proteolytic, and vascular protective effects. Bromelain, a proteolytic enzyme derived from pineapple stems, facilitates the breakdown of proteins, thereby reducing inflammation and edema in various inflammatory conditions. Trypsin, another proteolytic enzyme, complements Bromelain by accelerating the degradation of inflammatory mediators and promoting tissue repair. Rutoside, a bioflavonoid, exhibits strong antioxidant properties and enhances capillary strength, reducing vascular permeability and preventing microvascular bleeding. The synergistic action of these components makes Enzrid-DS effective in managing acute and chronic inflammatory disorders, including post-traumatic edema, surgical swelling, and inflammatory conditions of the musculoskeletal system. Additionally, it may aid in improving microcirculation and reducing oxidative stress associated with vascular disorders. Enzrid-DS is typically administered orally under medical supervision, with dosage tailored to the severity of the condition and patient response. Caution is advised in patients with hypersensitivity to any component or those with bleeding disorders. Overall, Enzrid-DS Tablet offers a comprehensive approach to inflammation management by combining enzymatic and antioxidant mechanisms to promote faster recovery and symptom relief.